RT Journal Article
SR Electronic
T1 Pre-diagnosis blood DNA methylation profiling of twin pairs discordant for breast cancer points to the importance of environmental risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.15.23293985
DO 10.1101/2023.08.15.23293985
A1 Bode, Hannes Frederik
A1 He, Liang
A1 Hjelmborg, Jacob V.B.
A1 Kaprio, Jaakko
A1 Ollikainen, Miina
YR 2024
UL http://medrxiv.org/content/early/2024/03/12/2023.08.15.23293985.abstract
AB Background Assessment of breast cancer (BC) risk generally relies on mammography, family history, reproductive history, and genotyping of major mutations. However, assessing the impact of environmental factors, such as lifestyle, health related behavior or external exposures, is still challenging. DNA methylation (DNAm), capturing both genetic and environmental effects, presents a promising opportunity. Previous studies have identified associations and predicted the risk of BC using DNAm in blood, however, these studies did not distinguish between genetic and environmental contributions to these DNAm sites. In this study, associations between DNAm and BC are assessed using paired twin models, which control for shared genetic and environmental effects, allowing testing for associations between DNAm and non-shared environmental exposures and behavior.Results Pre-diagnosis blood samples of 32 monozygotic (MZ) and 76 dizygotic (DZ) female twin pairs discordant for BC were collected at the mean age of 56.0 years, with the mean age at diagnosis 66.8 and censoring 75.2 years. We identified 212 CpGs (p<6.4*10−8) and 15 DMRs associated with BC risk across all pairs using paired Cox proportional hazard models. All but one of the BC risk associated CpGs were hypomethylated and 198/212 CpGs had their DNAm associated with BC risk independent of genetic effects. According to previous literature, at least five of the top CpGs were related to estrogen signaling. Following a comprehensive two-sample Mendelian Randomization analysis, we found evidence supporting a dual causal impact of DNAm at cg20145695 (gene body of NXN, rs480351) with increased risk for estrogen-receptor positive BC and decreased risk for estrogen-receptor negative BC.Conclusion While causal effects of DNAm on BC risk are rare, most of the identified CpGs associated with the risk of BC appear to be independent of genetic effects. This suggests that DNAm could serve as a valuable biomarker for environmental risk factors for BC, and may offer potential benefits as a complementary tool to current risk assessment procedures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the European Union's Horizon 2020 Research and Innovation Programme, Marie Skłodowska-Curie (JK, grant number 859860). This project has received further funding from the Research Council of Finland (MO, grant numbers 297908, 328685 & JK, grant 336823) and the Sigrid Juselius Foundation (MO and JK). The Danish part of the research was funded AgeCare program of the Academy of Geriatric Cancer Research, Odense University Hospital, as well as by a scholarship from the Faculty of Health Sciences, University of Southern Denmark.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained before the beginning of the FTC studies in 1975, and upon every contact with the study subjects. When clinical investigations were undertaken with sampling of biological material, written informed consent was obtained. Ethics approval of these procedures was provided in multiple studies, the last one on the transfer of biological samples to the THL Biobank by the Hospital District of Helsinki and Uusimaa ethics board in 2018 (#1799/2017). Permission for register linkage to the Finnish Cancer Registry was given by the Finnish Social and Health Data Permit Authority Findata (latest THL/6353/14.06.00/2023). The two Danish twin studies (LSADT and MADT) were approved by the Regional Committees on Health Research Ethics for Southern Denmark (S-VF-19980072), and written informed consents were obtained from all participants. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBCbreast cancerDTSDanish Twin StudyDZdizygoticEPICIllumina Infinium MethylationEPIC BeadChipER+ BCestrogen receptor positive breast cancerER-BCestrogen receptors negative breast cancerEWASepigenome wide association studyFTCFinnish Twin Cohort StudyGWASgenome wide association studyHRHazard RatioIVinstrumental variableLSADTLongitudinal Study of Aging in Danish Twins StudyMADTMiddle Age Danish Twins StudyMRMendelian randomizationMZmonozygoticOROdds RatioUKBBUK Biobank450KInfinium HumanMethylation450 BeadChip